Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol’s New Products Meet Early Launch Expectations

Even So, Currency Changes Lead To Lowered Revenue Guidance

Executive Summary

Sales rose significantly for Reblozyl and for Abecma and Breyanzi, despite manufacturing challenges for the two cell therapies. Newly approved Opdualag and Camzyos are off to encouraging starts.

You may also be interested in...



BMS’s Phase III Reblozyl Trial Hits Mark In First-Line, Lower-Risk Myelodysplastic Syndrome

The drug’s success in the Phase III COMMANDS trial could double its addressable market, though some analysts said durability remains a question.

Dr Reddy’s Debuts Two Revlimid Exclusives As Part Of Complete Launch In US

Dr Reddy’s Laboratories is set to reap the rewards of a significant US generic launch – albeit one with a limited volume caveat decreed by a patent-litigation settlement deal – after it began selling its generic of Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid.

US Pharmas Display Defensive Mettle But Headwinds Mount

US big pharma manufacturers generally delivered sales and earnings growth in the second quarter and reaffirmed guidance despite currency headwinds; US drug pricing legislation could present a tipping pressure point.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel